Apellis Pharmaceuticals I...

18.20
0.04 (0.22%)
At close: Apr 17, 2025, 3:59 PM
18.15
-0.27%
Pre-market: Apr 21, 2025, 06:07 AM EDT

Apellis Pharmaceuticals Statistics

Share Statistics

Apellis Pharmaceuticals has 125.52M shares outstanding. The number of shares has increased by 3.42% in one year.

Shares Outstanding 125.52M
Shares Change (YoY) 3.42%
Shares Change (QoQ) 0.9%
Owned by Institutions (%) 99.99%
Shares Floating 104.48M
Failed to Deliver (FTD) Shares 1.67K
FTD / Avg. Volume 0.09%

Short Selling Information

The latest short interest is 22.51M, so 17.93% of the outstanding shares have been sold short.

Short Interest 22.51M
Short % of Shares Out 17.93%
Short % of Float 24.48%
Short Ratio (days to cover) 10.4

Valuation Ratios

The PE ratio is -19.98 and the forward PE ratio is 107.06. Apellis Pharmaceuticals's PEG ratio is 0.31.

PE Ratio -19.98
Forward PE 107.06
PS Ratio 5.57
Forward PS 1.3
PB Ratio 17.3
P/FCF Ratio -44.79
PEG Ratio 0.31
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Apellis Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.25, with a Debt / Equity ratio of 2.06.

Current Ratio 4.25
Quick Ratio 3.81
Debt / Equity 2.06
Debt / EBITDA -1.99
Debt / FCF -5.32
Interest Coverage -5.85

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $1.01M
Profits Per Employee $-280.68K
Employee Count 705
Asset Turnover 0.8
Inventory Turnover 1.45

Taxes

Income Tax 1.16M
Effective Tax Rate -0.59%

Stock Price Statistics

The stock price has increased by -61.71% in the last 52 weeks. The beta is 0.84, so Apellis Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.84
52-Week Price Change -61.71%
50-Day Moving Average 24.37
200-Day Moving Average 30.88
Relative Strength Index (RSI) 28.14
Average Volume (20 Days) 1.96M

Income Statement

In the last 12 months, Apellis Pharmaceuticals had revenue of 709.95M and earned -197.88M in profits. Earnings per share was -1.6.

Revenue 709.95M
Gross Profit 592.23M
Operating Income -236.39M
Net Income -197.88M
EBITDA -236.39M
EBIT -237.11M
Earnings Per Share (EPS) -1.6
Full Income Statement

Balance Sheet

The company has 411.29M in cash and 469.78M in debt, giving a net cash position of -58.49M.

Cash & Cash Equivalents 411.29M
Total Debt 469.78M
Net Cash -58.49M
Retained Earnings -3.04B
Total Assets 885.05M
Working Capital 603.45M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -87.87M and capital expenditures -403K, giving a free cash flow of -88.27M.

Operating Cash Flow -87.87M
Capital Expenditures -403K
Free Cash Flow -88.27M
FCF Per Share -0.71
Full Cash Flow Statement

Margins

Gross margin is 83.42%, with operating and profit margins of -33.3% and -27.87%.

Gross Margin 83.42%
Operating Margin -33.3%
Pretax Margin -27.71%
Profit Margin -27.87%
EBITDA Margin -33.3%
EBIT Margin -33.3%
FCF Margin -12.43%

Dividends & Yields

APLS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for APLS is $40, which is 119.8% higher than the current price. The consensus rating is "Buy".

Price Target $40
Price Target Difference 119.8%
Analyst Consensus Buy
Analyst Count 18
Stock Forecasts

Scores

Altman Z-Score -1.47
Piotroski F-Score 3